DJ-1 Could Predict Worse Prognosis in Esophageal Squamous Cell Carcinoma

2008 ◽  
Vol 17 (12) ◽  
pp. 3593-3602 ◽  
Author(s):  
H.-F. Yuen ◽  
Y.-P. Chan ◽  
S. Law ◽  
G. Srivastava ◽  
M. El-tanani ◽  
...  
Author(s):  
Xiuping Yang ◽  
Baoai Han ◽  
Zuhong He ◽  
Ya Zhang ◽  
Kun Lin ◽  
...  

The abnormality of RNA-binding proteins (RBPs) is closely related to the tumorigenesis and development of esophageal squamous cell carcinoma (ESCC), and has been an area of interest for research recently. In this study, 162 tumors and 11 normal samples are obtained from The Cancer Genome Atlas database, among which 218 differentially expressed RBPs are screened. Finally, a prognostic model including seven RBPs (CLK1, DDX39A, EEF2, ELAC1, NKRF, POP7, and SMN1) is established. Further analysis reveals that the overall survival (OS) rate of the high-risk group is lower than that of the low-risk group. The area under the receiver operating characteristic (ROC) curve (AUC) of the training group and testing group is significant (AUCs of 3 years are 0.815 and 0.694, respectively, AUCs of 5 years are 0.737 and 0.725, respectively). In addition, a comprehensive analysis of seven identified RBPs shows that most RBPs are related to OS in patients with ESCC, among which EEF2 and ELCA1 are differentially expressed at the protein level of ESCC and control tissues. CLK1 and POP7 expressions in esophageal cancer tumor samples are undertaken using the tissue microarray, and show that CLK1 mRNA levels are relatively lower, and POP7 mRNA levels are higher compared with non-cancerous esophageal tissues. Survival analysis reveals that a higher expression of CLK1 predicts a significant worse prognosis, and a lower expression of POP7 predicts a worse prognosis in esophageal cancer. These results suggest that CLK1 may promote tumor progression, and POP7 may hinder the development of esophageal cancer. In addition, gene set enrichment analysis reveals that abnormal biological processes related to ribosomes and abnormalities in classic tumor signaling pathways such as TGF-β are important driving forces for the occurrence and development of ESCC. Our results provide new insights into the pathogenesis of ESCC, and seven RBPs have potential application value in the clinical prognosis prediction of ESCC.


Oncology ◽  
2021 ◽  
Vol 100 (1) ◽  
pp. 39-47
Author(s):  
Tadashi Shiraishi ◽  
Takeshi Toyozumi ◽  
Haruhito Sakata ◽  
Kentaro Murakami ◽  
Masayuki Kano ◽  
...  

<b><i>Introduction:</i></b> We determined the soluble programmed cell death-1 ligand-1 (sPD-L1) concentration in patients with esophageal squamous cell carcinoma (ESCC), and confirmed the PD-L1 expression in resected specimens. <b><i>Methods:</i></b> Blood samples were collected from 73 patients with histologically proven ESCC. The serum levels of sPD-L1 were measured using an enzyme-linked immunosorbent assay. The correlations between the sPD-L1 concentration and the expression of PD-L1 in tumor specimens and tumor depth, lymph node metastasis, disease stage, and various laboratory data were assessed. <b><i>Results:</i></b> sPD-L1 levels in patients with high PD-L1 expression levels in tumor tissue were significantly higher than in patients with low PD-L1 expression levels (<i>p</i> = 0.042). The OS of the sPD-L1-high group was significantly worse than that of the low group (<i>p</i> = 0.028). Similarly, patients in whom a tissue specimen was PD-L1-positive group showed significantly poorer OS. <b><i>Conclusion:</i></b> The sPD-L1 concentration was correlated with the PD-L1 expression in tissues. Patients with PD-L1-positive tissue specimens showed significantly higher sPD-L1 levels in comparison to PD-L1-negative cases. Furthermore, patients with high sPD-L1 expression levels had a significantly worse prognosis than those with low sPD-L1 expression levels, and patients with a PD-L1-positive tissue specimen had a significantly worse prognosis than patients in whom the tissue specimen showed a low PD-L1 expression level.


2012 ◽  
Vol 63 (2) ◽  
pp. 195-195
Author(s):  
K. Minashi ◽  
T. Yano ◽  
T. Kojima ◽  
M. Onozawa ◽  
K. Nihei ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document